REG - GSK PLC - Director/PDMR Shareholding
17/01/2023 15:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230117:nRSQ0214Na&default-theme=true
RNS Number : 0214N GSK PLC 17 January 2023
GSK plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms E Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held
in the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 577
£14.3100 480
£14.3100 719
d) Aggregated information
Aggregated volume Price 1,776
£14.3100
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr I Mackay
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held
in the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 390
£14.3100 333
£14.3100 497
d) Aggregated information
Aggregated volume Price 1,220
£14.3100
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr H Barron
b) Position/status Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends
paid to shareholders on 12 January 2023 on ADSs held in the Company's Deferred
Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$35.1500 326
$35.1500 247
$35.1500 390
d) Aggregated information
Aggregated volume Price 963
$35.1500
e) Date of the transaction 2023-01-16
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held
in the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 75
£14.3100 69
£14.3100 112
d) Aggregated information
Aggregated volume Price 256
£14.3100
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr J Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held
in the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 107
£14.3100 83
£14.3100 139
d) Aggregated information
Aggregated volume Price 329
£14.3100
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held
in the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 45
£14.3100 42
£14.3100 64
d) Aggregated information
Aggregated volume Price 151
£14.3100
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr L Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held
in the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 174
£14.3100 130
£14.3100 236
d) Aggregated information
Aggregated volume Price 540
£14.3100
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends
paid to shareholders on 12 January 2023 on ADSs held in the Company's Deferred
Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$35.1500 23
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-01-16
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held
in the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 128
£14.3100 102
£14.3100 156
d) Aggregated information
Aggregated volume Price 386
£14.3100
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held
in the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 90
£14.3100 77
£14.3100 142
d) Aggregated information
Aggregated volume Price 309
£14.3100
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr P Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held
in the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 74
£14.3100 59
£14.3100 98
d) Aggregated information
Aggregated volume Price 231
£14.3100
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Waterhouse
b) Position/status CEO, ViiV Healthcare
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 January 2023 on Ordinary Shares held
in the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 123
£14.3100 104
d) Aggregated information
Aggregated volume Price 227
£14.3100
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms E Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 12 January 2023 on Ordinary Shares held in the Company's
Performance Share Plan subject to a 2-year holding period
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 6,304.099
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2023-01-16
f)
Place of the transaction
London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr I Mackay
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 12 January 2023 on Ordinary Shares held in the Company's
Performance Share Plan subject to a 2-year holding period
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3100 1,517.833
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-01-16
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFIFLWEDSEDFRecent news on GSK
See all newsREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - 1st Quarter Results
AnnouncementREG - GSK PLC - US FDA accepts new indication filing for Jemperli
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
Announcement